Newsroom

Twitter

Videos

Photos

20160128 EGA Regulatory and Scientific Affairs Conferenc

Oncology, the new era for biosimilar medicines

8 September 2017

With more than 10 years of positive experience and 700 […]

Read more

Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health

16 June 2017

Biosimilar medicines are transforming treatment by enabling better access to […]

Read more

EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access

23 May 2017

The European Semester Country Specific Recommendations show that healthcare systems […]

Read more

Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe

9 May 2017

The new report on The Impact of Biosimilar Competition in […]

Read more

Industry Welcomes the 3rd European Commission Workshop on Biosimilar Medicines

5 May 2017

The European pharmaceutical industry welcomes the 3rd workshop on access […]

Read more

Over 100 Participants Explore Opportunities to Ensure Universal Access to Health

27 April 2017

Over 100 participants explored different ways and opportunities to ensure […]

Read more

Biosimilar Medicines: a Game Changer for Oncology Care

23 March 2017

With 10 years of positive experience with biosimilar medicines, medical […]

Read more

Stimulating Investment in European Generic, Biosimilar and Value Added Medicines through a Transparent Legal Environment

22 March 2017

Key authorities, eminent lawyers and industry leaders discussed today in […]

Read more

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

14 March 2017

On 9th March, IFPMA launched jointly with EFPIA and EBE […]

Read more

Experience and Evidence of Physician-led Switching of Biological Medicines Fully Recognised in Europe

9 March 2017

Medicines for Europe welcomes the fact that EFPIA (supported by […]

Read more

Subscribe to our newsletter

[contact-form-7 id="1638" title="Newsletter subscription"]